TRUQAP 160 MG FILM COATED TABLETS
CAPIVERSETIB
What it does
Capiversetib is a medication that may be used to help manage certain health conditions.
Commonly used for: cancer (malignancy), other specific conditions as determined by a healthcare provider
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.
Source this medicineRegistration & product details
Source: Pharmacy and Poisons Board · fetched 2026-01-28 19:16:41 · updated 2026-10-20 02:14:25
About this medicine
Capiversetib is a medication that may be used to help manage certain health conditions.
What it treats
- cancer (malignancy)
- other specific conditions as determined by a healthcare provider
How it works
Capiversetib works by targeting specific pathways in the body to help slow down or stop the growth of cancer cells.
Who it's for
This medication is intended for patients with specific types of cancer as guided by their doctor.
Cautions
- • Always inform your doctor about any other medications you are taking.
- • Discuss any existing health issues with your healthcare provider before starting this medication.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: capiversetib
Capiversetib is an investigational drug that is being explored primarily for its potential in treating various types of cancer, particularly those with specific genetic mutations. It acts as a selective inhibitor of the protein kinase AKT, which plays a crucial role in the signaling pathways that regulate cell growth, proliferation, and survival. By inhibiting AKT, capiversetib aims to disrupt these pathways and induce apoptosis in cancer cells.
Indications
- Breast cancer
- Prostate cancer
- Non-small cell lung cancer
- Ovarian cancer
Dosage
Children: Refer to specific clinical trial protocols or treatment guidelines for dosing instructions, as capiversetib is currently under investigation.
Adults: Refer to specific clinical trial protocols or treatment guidelines for dosing instructions, as capiversetib is currently under investigation.
Mechanism of action
Capiversetib selectively inhibits the AKT pathway, a critical pathway in the regulation of cell metabolism, growth, and survival. AKT is activated by various growth factors and is involved in multiple signaling cascades, including the mTOR pathway, promoting cancer cell proliferation and resistance to apoptosis. By blocking AKT activation, capiversetib can decrease the proliferation of cancer cells and enhance their susceptibility to other therapeutic agents.
Pharmacodynamics
The pharmacodynamics of capiversetib involve its ability to inhibit AKT activity, leading to reduced cell survival and proliferation in neoplastic cells. This inhibition can also enhance the effects of other anticancer therapies, potentially overcoming resistance mechanisms that are common in cancer treatment. The drug demonstrates a dose-dependent effect on tumor growth inhibition, which is essential for optimizing therapeutic regimens in clinical settings.
Pharmacokinetics
Capiversetib undergoes metabolic processing primarily through the liver, with the cytochrome P450 system being involved in its biotransformation. The drug exhibits a half-life that allows for once-daily dosing, facilitating patient compliance. Its absorption, distribution, metabolism, and excretion (ADME) characteristics are being studied to establish optimal dosing regimens and to understand potential drug-drug interactions.
Contra-indications
- Hypersensitivity to capiversetib or any of its components
- Severe liver impairment
Adverse effects
- Nausea
- Diarrhea
- Fatigue
- Rash
- Elevated liver enzymes
- Hyperglycemia
Interactions
- Potential interactions with CYP3A4 inhibitors and inducers
- May interact with other antidiabetic agents leading to increased risk of hypoglycemia
Precautions
- Use with caution in patients with a history of liver disease
- Monitor blood glucose levels in diabetic patients
- Assess for signs of hypersensitivity reactions
Pregnancy
There is limited data on the use of capiversetib during pregnancy. It should be used only if the potential benefit justifies the potential risk to the fetus.
Breast-feeding
It is unknown whether capiversetib is excreted in human milk. Caution should be exercised when administering to breastfeeding women.
Storage
Store at room temperature, away from moisture and heat. Keep out of reach of children.
Formulations
- Oral tablet
- Capsule
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.